New Obesity Drug Helps Patients Lose 70 Pounds in 80 Weeks

For the first time, a medication has matched the dramatic weight loss results that only surgery could achieve before.

Eli Lilly's experimental drug retatrutide helped patients lose an average of 70 pounds over 80 weeks in a major trial presented at the American Diabetes Association meeting in New Orleans. Nearly half of the 2,500 participants lost 30% or more of their body weight, and two-thirds of those on the highest dose dropped below the obesity threshold entirely.

"That's an incredible number to see," said Dan Skovronsky, Lilly's chief scientific officer. "That level had previously been tied only to surgery."

The drug works differently than existing treatments by targeting three hormones instead of one or two. Patients on the 12 mg dose lost 28.3% of their weight compared to just 2.2% for those taking a placebo, among participants who stayed on the medication throughout the study.

The breakthrough comes with bonus benefits beyond weight loss. The same trial showed the drug reduced severe sleep apnea symptoms by more than 60% and cut knee pain from osteoarthritis by up to 73%. These additional health improvements could help patients address multiple chronic conditions with one treatment.

Timing the approval is still uncertain since the Food and Drug Administration hasn't reviewed the application yet. Lilly expects doctors will initially prescribe it for patients with higher body mass indexes, though a lower 4 mg dose helped patients lose 19% of their weight with fewer side effects.

The Ripple Effect

The medication's arrival coincides with a major shift in how Americans can access obesity care. Starting in July, millions of Medicare beneficiaries will pay just $50 monthly for weight loss medications that previously cost hundreds of dollars out of pocket.

This policy change signals growing recognition that obesity treatment belongs in mainstream healthcare. Dave Ricks, Lilly's CEO, argues the conversation needs reframing. "Obesity care should be health care," he told reporters while sharing that his company is studying health costs and outcomes among employees using these medications.

Safety concerns appear manageable based on trial results. The most common side effects were gastrointestinal issues, and researchers found no cardiac or liver problems. A slightly higher rate of urinary tract infections was mostly mild and resolved during treatment.

Lilly plans to sell retatrutide through its direct-to-consumer platform LillyDirect once approved, making access easier for patients. The company currently serves fewer than 20% of its own employees who use similar drugs for weight loss, suggesting sustainable demand levels.

The breakthrough represents hope for the millions of Americans struggling with obesity and related health conditions who haven't found success with other approaches.